Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study
<p><strong>Objective</strong> To evaluate the safety and clinical efficacy of nusinersen in patients older than 7 months with spinal muscular atrophy type 1 (SMA1). <p><strong>Methods</strong> Patients with SMA1 were treated with nusinersen by intrathecal injecti...
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
2018
|